NYSE:ABBVBiotechs
AbbVie Expands SKYRIZI Access As Immunology And Dividend Story Evolves
AbbVie (NYSE:ABBV) is expanding access to SKYRIZI for ulcerative colitis patients in Canada through new formulary listings and positive reimbursement recommendations.
The company is presenting new clinical outcome data for SKYRIZI and RINVOQ in inflammatory bowel diseases.
AbbVie is extending the commercial and clinical reach of its immunology portfolio while pursuing digital transformation efforts in life sciences.
For investors watching NYSE:ABBV, these updates highlight fresh activity in...